2009
DOI: 10.1055/s-0029-1222032
|View full text |Cite
|
Sign up to set email alerts
|

Novomix® 30 hat bei dreimal täglicher Gabe ein vergleichbares Wirkprofil wie eine Basis-Bolus-Therapie mit den Analog-Insulinen Glargin und Glulisine

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles